Company Filing History:
Years Active: 2020
Title: The Innovative Contributions of Robert Motzer
Introduction
Robert Motzer is a distinguished inventor based in Ridgewood, NJ (US). He is known for his significant contributions to the field of cancer research, particularly in the development of biomarkers that can predict the effectiveness of rapamycin analogs in cancer treatment. His work has the potential to improve therapeutic strategies for patients suffering from kidney cancer.
Latest Patents
Motzer holds a patent titled "Biomarkers for response to rapamycin analogs." This invention focuses on utilizing one or more biomarkers to assess the likelihood that a rapamycin analog will yield an anti-cancer effect in a subject. The patent is grounded in experimental results that employed an integrated next-generation sequencing approach. This approach interrogated spatially separated tumor specimens from the same individuals to understand intra-tumor and intertumor heterogeneity. The findings revealed the oncogenomic basis for the exceptional therapeutic benefits of rapalogs in kidney cancer patients. The invention also provides assay methods and kits for detecting loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function mutations in mTOR. These methods can be instrumental in selecting appropriate therapeutic regimens for cancer patients.
Career Highlights
Robert Motzer is affiliated with the Memorial Sloan Kettering Cancer Center, where he continues to advance cancer research. His work has garnered attention for its innovative approach to understanding the genetic factors that influence treatment responses in cancer patients.
Collaborations
Motzer has collaborated with notable colleagues, including James Hsieh and Michael Berger. Their combined expertise has contributed to the advancement of cancer research and the development of effective treatment strategies.
Conclusion
Robert Motzer's innovative work in cancer research, particularly through his patent on biomarkers for rapamycin analogs, showcases his commitment to improving patient outcomes. His contributions are vital in the ongoing fight against cancer, and his collaborations further enhance the impact of his research.